Sylics was acquired by InnoSer. To see what’s new, read below or use the navigation bar to find the information you need.

    Multiple Sclerosis (de- and re-myelination)

    Test novel compounds targeting Multiple Sclerosis with the support of our services in de- and re-myelinating models

    Home » Neurology Research Models and Services  » Multiple Sclerosis (de- and re-myelination) 
    Multiple sclerosis (MS) is the most common chronic inflammatory, demyelinating, and neurodegenerative disease. The pathological hallmark of MS are the formation of demyelinating lesions in the brain and spinal cord. The core neuropathology of MS is the loss of oligodendrocytes and myelin sheaths, leading to axonal damage and neuroinflammation. 
    InnoSer offers unique preclinical contract research services using in vivo MS models of de- and re-myelienation. In the cuprizone model of MS, cuprizone induces oligodendrocyte death and reversible myelination, recapitulating the pathophysiology of MS. In the cuprizone + rapamycin model, the addition of mTOR inhibitor, rapamycin, prevents spontaneous re-myelination by newly differentiated oligodendrocytes, thereby creating a more severe demyelinating phenotype.  

    Take advantage of InnoSer’s expertise, flexibility and collaborative approach for your research. We support our clients in identifying new drugs or applications, characterizing their pharmacological properties, and conducting safety and efficacy testing with state-of-the-art readout capabilities and histopathological analysis. 

    Multiple sclerosis models that InnoSer offers:

    • Cuprizone model (de- and remyelination).
    • Cuprizone + rapamycin model (demyelination).

    Find the right model for you.

    Compare our model capabilities and discover which of our neurology platforms suits your research needs

    Belgian based preclinical neurology CRO mouse models

    Key readouts

    Test the efficacy of your treatments with the following commonly used behavioral tests:

    Assess the efficacy of your treatments with the following biological readouts:

    • IHC: Myelin, immune response, astrocytes, de/remyelination (MBP, PLP), Inflammation (macrophages, T- and B-cells, microglia, astrocytes) 
    • mRNA or protein of inflammatory mediators, receptors, etc. 

    Related rare disease model options

    Neurology Platform Overview

    Highly relevant neurology models to facilitate preclinical drug development.

    CMT1A (C3-PMP22)

    InnoSer offers a fee-for-service C-3PMP22 model to research novel therapies against Charcot Marie Tooth Type 1A. 

    Vanishing White Matter

    InnoSer offers unique services with an Eif2b4 / Eif2b5 mouse model of vanishing white matter (VWM).

    AAALAC Accreditation

    InnoSer has earned the AAALAC accreditation, demonstrating our commitment to responsible animal care and use. AAALAC International is a nonprofit organization that promotes the humane treatment of animals in science through voluntary accreditation and assessment programs. Our accreditation is valid for three years, incl. 2023. Read more about the AAALAC accreditation programme here.

    AAALAC logo

    Animal Welfare

    The 3Rs impact everything from policy and regulatory change to the development and uptake of new technologies and approaches. This is why Innoser has ongoing commitment and monitoring of these processes. The steps we practice maximize our ability to replace, reduce and refine animal involvement and facilitate our commitment to these principles when it comes to research and drug development.

    Need more information?

    If you have any questions about how we can help accelerate your research,

    then let us know